Home Cart Sign in  
Chemical Structure| 675576-98-4 Chemical Structure| 675576-98-4

Structure of Nutlin-3a
CAS No.: 675576-98-4

Chemical Structure| 675576-98-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Nutlin-3a (Rebemadlin), the active enantiomer of Nutlin-3, is a potent MDM2 inhibitor with an IC50 of 90 nM. It disrupts MDM2-p53 interactions, stabilizes p53 protein, and induces cell autophagy and apoptosis, showing potential for studying TP53 wild-type ovarian carcinomas.

Synonyms: Rebemadlin; (-)-Nutlin-3

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Nutlin-3a

CAS No. :675576-98-4
Formula : C30H30Cl2N4O4
M.W : 581.49
SMILES Code : O=C1NCCN(C(N2[C@H](C3=CC=C(Cl)C=C3)[C@H](C4=CC=C(Cl)C=C4)N=C2C5=CC=C(OC)C=C5OC(C)C)=O)C1
Synonyms :
Rebemadlin; (-)-Nutlin-3
MDL No. :MFCD14636430
InChI Key :BDUHCSBCVGXTJM-WUFINQPMSA-N
Pubchem ID :11433190

Safety of Nutlin-3a

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P280-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
U-2OS osteosarcoma cells 10 µM 14 days Induced senescence rather than apoptosis Neuro Oncol. 2012 Jul;14(7):859-69.
HCT116 p53+/+ and HCT116 p53−/− cells 10 µM 24 hours Detected p53 accumulation and down-regulation of ING2 expression in p53 wild-type cells Neuro Oncol. 2012 Jul;14(7):859-69.
HCT116 cells 5 µM 24 hours Nutlin-3a treatment caused cell cycle arrest in G1 and G2 phases and promoted endoreduplication and the generation of tetraploid cells Cancer Res. 2008 Oct 15;68(20):8260-8.
U2OS cells 5 µM 24 hours Nutlin-3a treatment caused cell cycle arrest in G1 and G2 phases and promoted endoreduplication and the generation of tetraploid cells Cancer Res. 2008 Oct 15;68(20):8260-8.
SW 1990 cells 10 µM Nutlin-3a, as an MDM2 inhibitor, inhibits MDM2-p53 interactions and stabilizes the p53 protein, thereby inducing cell autophagy and apoptosis. Mol Oncol. 2022 Mar;16(5):1200-1217.
HPAC cells 10 µM Nutlin-3a, as an MDM2 inhibitor, inhibits MDM2-p53 interactions and stabilizes the p53 protein, thereby inducing cell autophagy and apoptosis. Mol Oncol. 2022 Mar;16(5):1200-1217.
HCT116 p21 KO cells 10 μM 8 h Nutlin-3a treatment led to stabilization of p53 and restored the induction of PUMA in the presence of either growth factor. Oncogene. 2010 Mar 18;29(11):1622-32.
ALST cells 10 μM 24 h To test the activation of WT TP53 by Nutlin-3a, results showed that Nutlin-3a increased WT TP53 activity. Neoplasia. 2015 Oct;17(10):789-803.
OVCA433 cells 10 μM 24 h To test the activation of WT TP53 by Nutlin-3a, results showed that Nutlin-3a increased WT TP53 activity. Neoplasia. 2015 Oct;17(10):789-803.
OVCA420 cells 20 μM 24 h To test the effect of Nutlin-3a on cell viability, results showed that OVCA420 cells were less sensitive to Nutlin-3a. Neoplasia. 2015 Oct;17(10):789-803.
OVCAR3 cells 20 μM 24 h To test the effect of Nutlin-3a on cell viability, results showed that OVCAR3 cells were less sensitive to Nutlin-3a. Neoplasia. 2015 Oct;17(10):789-803.
HepG2 cells 10 µM Nutlin-3a treatment increased ApoB expression and secretion and reduced lipid accumulation. Adv Sci (Weinh). 2022 Jul;9(20):e2200742.
Primary hepatocytes 10 µM Nutlin-3a treatment increased ApoB expression and secretion and reduced lipid accumulation. Adv Sci (Weinh). 2022 Jul;9(20):e2200742.
LNCaP cells 0.5 μM 5 days Nutlin-3a activates p53 signaling, inhibits LNCaP cell growth, and induces cell cycle arrest and apoptosis. Mol Cancer. 2011 May 3;10:49.
22Rv1 cells 5 μM 48 h Nutlin-3a combined with androgen deprivation enhanced the apoptotic response in 22Rv1 cells. Mol Cancer. 2011 May 3;10:49.
DU145 cells 5 μM 48 h No significant increase in apoptosis was observed in DU145 cells treated with Nutlin-3a. Mol Cancer. 2011 May 3;10:49.
MCF-7 cells 8 μM 12 h Using GRO-seq analysis, the production of enhancer RNAs (eRNAs) induced by nutlin-3a was detected, revealing p53-regulated enhancer regions. Nat Commun. 2015 Mar 27;6:6520.
MCF-7 cells 8 μM 12 h Through RNA sequencing, 194 nutlin-3a-responsive long non-coding RNAs (lncRNAs) were identified, and the importance of LED in the p53 transcriptional response was validated. Nat Commun. 2015 Mar 27;6:6520.
PA-1 cells 40 μM 48 h To evaluate the effect of Nutlin-3a on the p53 signaling pathway, results showed upregulation of p53 expression Theranostics. 2017 Oct 13;7(18):4566-4576.
MCF-7 cells 40 μM 48 h To evaluate the effect of Nutlin-3a on the p53 signaling pathway, results showed upregulation of p53 expression Theranostics. 2017 Oct 13;7(18):4566-4576.
MDA-MB-231 15 µM 5 days To evaluate the inhibitory effects of Nutlin-3a and carboplatin on cell proliferation, results showed that the combination of Nutlin-3a and carboplatin had a synergistic effect, significantly inhibiting cell proliferation Mol Cancer Ther. 2015 Dec;14(12):2850-63.
TMD231 15 µM 5 days To evaluate the inhibitory effects of Nutlin-3a and carboplatin on cell proliferation, results showed that the combination of Nutlin-3a and carboplatin had a synergistic effect, significantly inhibiting cell proliferation Mol Cancer Ther. 2015 Dec;14(12):2850-63.
MDA-MB-468 15 µM 5 days To evaluate the inhibitory effects of Nutlin-3a and carboplatin on cell proliferation, results showed that the combination of Nutlin-3a and carboplatin had a synergistic effect, significantly inhibiting cell proliferation Mol Cancer Ther. 2015 Dec;14(12):2850-63.
MCF-7 15 µM 5 days To evaluate the inhibitory effects of Nutlin-3a and carboplatin on cell proliferation, results showed that the combination of Nutlin-3a and carboplatin had a synergistic effect, significantly inhibiting cell proliferation Mol Cancer Ther. 2015 Dec;14(12):2850-63.

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice C-Myc-deficient mice Gavage 200 mg/kg Twice daily for 3 days, with the final dose 3 h before irradiation Nutlin-3a treatment restored the apoptotic response in c-Myc-deficient mice, demonstrating that restoration of p53 function, via Nutlin treatment, is sufficient to rescue the blocked apoptosis phenotype in c-Myc-deficient enterocytes. Cell Death Differ. 2014 Jun;21(6):956-66
Nude mice Pancreatic cancer xenograft model Intratumoral injection 100 mg/kg Injected on days 1, 4, and 7, lasting for 21 days Nutlin-3a, as an MDM2 inhibitor, enhanced the antipancreatic cancer effect of USP22 overexpression, significantly slowing tumor growth. Mol Oncol. 2022 Mar;16(5):1200-1217.
Mice Whole body radiation (WBR) model Intraperitoneal injection 10 mg/kg 1 hour after radiation Nutlin-3a treatment restored the induction of PUMA and p53 in the presence of growth factors and significantly blocked the growth factor-mediated suppression of radiation-induced apoptosis. Oncogene. 2010 Mar 18;29(11):1622-32.
Mice CDAHFD-induced steatohepatitis model Intraperitoneal injection 10 mg/kg Twice daily for 1-2 weeks Nutlin-3a treatment alleviated CDAHFD-induced steatohepatitis by upregulating ApoB-mediated TG-VLDL secretion. Adv Sci (Weinh). 2022 Jul;9(20):e2200742.
Nude mice LNCaP xenograft model Oral 200 mg/kg Twice daily for 14 days Nutlin-3a combined with androgen deprivation significantly enhanced antitumor activity, leading to complete tumor regression and dramatically increased survival in mice. Mol Cancer. 2011 May 3;10:49.
Nude mice PA-1 xenograft model Intratumoral injection 10 mg/kg Every other day for 3 weeks To evaluate the tumor growth inhibitory effect of Nutlin-3a, results showed a tumor growth inhibition rate of 30% Theranostics. 2017 Oct 13;7(18):4566-4576.
Mice TMD231 orthotopic mammary fat pad model Oral and intraperitoneal injection 200 mg/kg Twice weekly for 4 weeks To evaluate the inhibitory effects of Nutlin-3a and carboplatin combination on primary tumor growth and lung metastasis, results showed that the combination treatment significantly inhibited tumor growth and lung metastasis with minimal toxicity to normal tissues Mol Cancer Ther. 2015 Dec;14(12):2850-63.

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.72mL

0.34mL

0.17mL

8.60mL

1.72mL

0.86mL

17.20mL

3.44mL

1.72mL

References

 

Historical Records

Categories